Introduction Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition
needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is …

Drug-resistant tuberculosis (DR-TB) remains a global crisis due to the increasing incidence
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …

Background Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) remain
low globally. Availability of newer drugs has given scope to develop regimens that can be …

Background Bedaquiline and delamanid are the first drugs of new classes registered for
tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects …

Background Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an
obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens …

Multidrug-resistant (MDR) isolates of Mycobacterium tuberculosis (MTB) remain a primary
global threat to the end of tuberculosis (TB) era. Delamanid (DLM) is a nitro-dihydro …

The World Health Organization (WHO) has produced this WHO operational handbook on
tuberculosis to provide practical advice to complement the latest WHO consolidated …

The role of mutations in genes associated with phenotypic resistance to bedaquiline (BDQ)
and delamanid (DLM) in Mycobacterium tuberculosis complex (MTBc) strains is poorly …

Background Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-
drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially …

Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6
months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK) …